|
?:authorAffiliation
|
-
[\'Department of Neurology, Columbia University, New York, NY, USA.\', \'Vienna General Hospital, Vienna, Austria.\', \'Boston University, Boston, MA, USA.\', \'University of Padova, Padova, Italy.\', \'University Health Network, Toronto, ON, Canada.\', \'Centro Hospitalar Universitário do Porto, Porto, Portugal.\', \'Referral Center for Cardiac Amyloidosis, Cardiology Department, APHP-Henri Mondor Hospital, Creteil, France.\', \'Mayo Clinic, Rochester, MN, USA.\', \'Penn Presbyterian Medical Center, Philadelphia, PA, USA.\', \'University of Calgary, Calgary, AB, Canada.\', \'Massachusetts General Hospital, Boston, MA, USA.\', \'National Amyloidosis Centre, Royal Free Hospital, London, UK.\', \'Hospital Puerta de Hierro of Madrid, Madrid, Spain.\', \'Cleveland Clinic, Cleveland, OH, USA.\', \'Akcea Therapeutics, Boston, MA, USA.\', \'University of Pennsylvania, Philadelphia, PA, USA.\', \'Columbia University, New York, NY, USA.\', \'University of Utah, Salt Lake City, UT, USA.\', \'Hospital Clinic, University of Barcelona, Barcelona, Spain.\', \'University Hospital of Münster, Münster, Germany.\', \'Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.\', \'Section of Cardiovascular Medicine, Department of Medicine and Amyloidosis Center, Boston University School of Medicine, Boston Medical Center, Boston, MA, USA. Frederick.Ruberg@bmc.org.\']
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}